Shots:

• Alexion acquires Achillion with initial all-cash transaction for ~$930M at $6.30/share- including Achillion's cash on hand of ~$230M- CVRs as clinical & regulatory milestones if achieved within specified periods which include $1.0 /share on FDA’s approval of Danicopan & $1.0/share in the initiation of P-III study of ACH-5228. The transaction is expected to be close in H1’2020
• The acquisition will expand Alexion’s pipeline with the addition of a clinical-stage portfolio of oral small molecule Factor D inhibitors
• The agreement provides enhance treatment for PNH patients experiencing EVH- (C3G) therapy & development platform for Factor D inhibition in additional alternative pathway complement-mediated rare diseases

Click here to­ read full press release/ article | Ref: Alexion | Image: Achillion